Company research
Biodexa Pharmaceuticals Plc
CIK 1643918Updated Sep 29, 2026
SecurityBDRX · NASDAQ · adr
Name history
Midatech Pharma Plc · through Mar 27, 2023
BDRX price & chart
Loading TradingView…
NASDAQ:BDRX on TradingView ↗About the company
We are a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, including gastrointestinal stromal tumors (“GIST”), familial adenomatous polyposis (“FAP”), non-muscle invasive bladder cancer (“NMIBC”), and type 1 diabetes (“T1D”).
In the news
No coverage from other publishers is available.
Recent filings
Show 5 more recent filings
Financials
FY 2025 · GBPSource
Source
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Profit or LossGBP | -6,384,000Source | -5,729,000Source | -7,079,000Source | -7,656,000Source |
| Additional Financial Items | ||||
| AdjustmentsForDecreaseIncreaseInTradeAccountReceivableGBP | 2,629,000Source | -5,975,000Source | 365,000Source | 7,000Source |
| AdjustmentsForIncomeTaxExpenseGBP | -105,000Source | -250,000Source | -406,000Source | -832,000Source |
| AdjustmentsForIncreaseDecreaseInTradeAccountPayableGBP | -913,000Source | 2,239,000Source | -207,000Source | 356,000Source |
| AdjustmentsForSharebasedPaymentsGBP | 170,000Source | 283,000Source | 28,000Source | 123,000Source |
| AdjustmentsForUnrealisedForeignExchangeLossesGainsGBP | 343,000Source | -93,000Source | 164,000Source | 9,000Source |
| IncomeTaxesPaidRefundClassifiedAsOperatingActivitiesGBP | -707,000Source | -129,000Source | -845,000Source | -678,000Source |
| InterestPaidClassifiedAsFinancingActivitiesGBP | 14,000Source | — | 13,000Source | 18,000Source |
| PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivitiesGBP | — | — | — | 178,000Source |
| ProceedsFromIssuingSharesGBP | 13,749,000Source | 8,312,000Source | 10,427,000Source | 243,000Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueGBP | — | — | 381,000Source | 699,000Source |
| Additional Financial Items | ||||
| AdministrativeExpenseGBP | 4,836,000Source | 3,793,000Source | 4,342,000Source | 4,542,000Source |
| BasicEarningsLossPerShareGBP/shares | -0Source | -0Source | — | — |
| DepreciationRightofuseAssetsGBP | 136,000Source | 135,000Source | 137,000Source | 166,000Source |
| DilutedEarningsLossPerShareGBP/shares | -0Source | -0Source | — | — |
| FinanceCostsGBP | 229,000Source | 165,000Source | 41,000Source | 53,000Source |
| FinanceIncomeGBP | 2,385,000Source | 3,385,000Source | 570,000Source | 497,000Source |
| IncomeTaxExpenseContinuingOperationsGBP | -105,000Source | -250,000Source | -406,000Source | -832,000Source |
| InterestExpenseOnLeaseLiabilitiesGBP | 10,000Source | 19,000Source | 28,000Source | 43,000Source |
| OtherIncomeGBP | 152,000Source | 31,000Source | 14,000Source | 22,000Source |
| PostemploymentBenefitExpenseDefinedContributionPlansGBP | 69,000Source | 67,000Source | 86,000Source | 98,000Source |
| ProfitLossBeforeTaxGBP | -6,489,000Source | -5,979,000Source | -7,485,000Source | -8,488,000Source |
| ProfitLossFromOperatingActivitiesGBP | -8,645,000Source | -9,199,000Source | -8,014,000Source | -8,932,000Source |
| ResearchAndDevelopmentExpenseGBP | 3,961,000Source | 5,437,000Source | 4,067,000Source | 5,111,000Source |
Offerings
Registration 333-299106
Registration 333-297473
Filing attachments
ex4_1.htm · F-1/A · 2026-07-30
EX-4.1 3 ex4_1.htm EXHIBIT 4.1 Exhibit 4.1 DESCRIPTION OF SECURITIES REGISTERED UNDER SECTION 12 OF THE EXCHANGE ACT The following description of the securities registered under Section 12 of the Securities Exchange Act of 1934, as amended of Biodexa Pharmaceuticals PLC (“Biodexa,” “we,” “us,” “our” or the “Company”) is a summary of the rights of our issued share capital and certain provisions of our articles of association. This summary does not purport to be complete and is qualified in …
Read attachment ↗ex4_1.htm · F-1 · 2026-07-15
EX-4.1 2 ex4_1.htm EXHIBIT 4.1 Exhibit 4.1 DESCRIPTION OF SECURITIES REGISTERED UNDER SECTION 12 OF THE EXCHANGE ACT The following description of the securities registered under Section 12 of the Securities Exchange Act of 1934, as amended of Biodexa Pharmaceuticals PLC (“Biodexa,” “we,” “us,” “our” or the “Company”) is a summary of the rights of our issued share capital and certain provisions of our articles of association. This summary does not purport to be complete and is qualified in …
Read attachment ↗